Watchlist Price Alert

ACADIA Pharmaceuticals In... (ACAD)

NASDAQ: ACAD · Real-Time Price · USD

17.46

0.53 (3.13%)

At close: May 09, 2025, 3:59 PM

17.58

0.66%

Pre-market: May 12, 2025, 04:04 AM EDT

3.13% (1D)

Bid	17.44
Market Cap	2.92B
Revenue (ttm)	957.8M
Net Income (ttm)	226.45M
EPS (ttm)	1.36
PE Ratio (ttm)	12.84
Forward PE	18.78
Analyst	Buy

Ask	17.99
Volume	2,385,347
Avg. Volume (20D)	1,742,050
Open	16.84
Previous Close	16.93
Day's Range	16.76 - 17.62
52-Week Range	13.40 - 20.68
Beta	0.47

About ACAD

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ACAD

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ACAD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

ACADIA Pharmaceuticals has released their quartely earnings on May 7, 2025:

Revenue of $244.32M exceeds estimates by $4.98M, with 18.70% YoY growth.

EPS of 0.11 exceeds estimates by 0.14, with 10.00% YoY growth.

Why Price Moved

4 days ago

+14.31%

ACADIA Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

2 months ago

+1.79%

Acadia Pharmaceuticals shares are trading higher after the company a Q4 EPS beat.

News

3 days ago · zacks.com

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.

4 days ago · zacks.com

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

5 days ago · seekingalpha.com

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Al Kildani - SVP of IR & Corporate Communications Catherine Owen Adams - CEO Tom...

5 days ago · zacks.com

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.

5 days ago · businesswire.com

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2025. “2025 is off to a strong start for Acadia, achi...

1 week ago · businesswire.com

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13...

6 days ago · zacks.com

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.

1 week ago · zacks.com

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · businesswire.com

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financ...

1 month ago · businesswire.com

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted induce...

Load More News